Cryptogenic fibrosing alveolitis: response to corticosteroid treatment and its effect on survival

M TURNER-WARWICK, B BURROWS, AND A JOHNSON

From the Cardiothoracic Institute, Brompton Hospital, London

ABSTRACT We have studied retrospectively 220 patients with cryptogenic fibrosing alveolitis (CFA) who were first seen between 1955-73 and had been followed up for at least four years until 1977. Seventy-seven patients had received no treatment and 143 had received corticosteroids. The only clinical difference between the groups was the age at presentation (untreated mean age 61 years $\pm$ 11 SD; treated mean age 56 years $\pm$ 11 SD $p < 0.001$). The influence of corticosteroid treatment has been assessed both in terms of the clinical, radiographic, and physiological response after four to eight weeks and in terms of survival, using a log rank method of analysis. Of 143 treated cases 127 had detailed follow-up information. Seventy-two (57%) had substantial subjective improvement of breathlessness but only 22 (17%) of the total showed additional objective improvement. The only factors significantly distinguishing the 72 subjective responders from the 55 non-responders, and which therefore might be used as predictors of response, were a younger age at presentation ($p < 0.001$) and less dyspnoea ($p < 0.02$). Analysis of survival data demonstrated that treated patients who showed an early good response to steroids had a markedly better survival than non-responders ($p < 0.001$). The survival curve for the untreated group lay between the two steroid groups. Analysis of the survival data suggests that steroid responsiveness relates particularly to a subgroup with an inherently better prognosis, which is characterised by a younger age and probably by a cellular histology not however necessarily typical of desquamative interstitial pneumonia. Nevertheless treatment appears to have an additional influence on survival especially in early disease, which is not observed in the untreated cases. A large number of factors are not related either to steroid responsiveness or to survival and these include the presence of associated "connective tissue" diseases, autoantibodies, and the duration of dyspnoea at presentation. It is concluded that biopsy information is valuable in assessment of potential to respond to steroids and that if steroid treatment is to be helpful it must be used at an early stage. The response is very variable and titration of the steroid dose against an individual patient's response is likely to give better results than adherence to arbitrary dose schedules.

Within the group of patients fulfilling the criteria for idiopathic interstitial pneumonia, it is well recognised that those having histological features of desquamative interstitial pneumonia (DIP) respond well to corticosteroids.^{1 2} Assessment of steroid response may be based on clinical criteria after a stated interval of treatment, or it may be considered in terms of survival. Some patients may have an improved survival because of arrest or stabilisation of active disease without the demonstration of objective or subjective improvement. Because of the heterogeneity of the condition identification of this group requires study of a large number of patients

for many years.

In spite of the difficulties of standardised diagnostic criteria for CFA, the variable histological features of activity at the time of presentation and the varied criteria used for assessing steroid responsiveness, the published results in a number of uncontrolled studies show considerable similarities.²⁻⁵ The factors relating to steroid responsiveness have not been studied in depth but it has been suggested that women and younger individuals respond better.⁶ Several reports indicate that those with a greater inflammatory cell infiltrate (including a cellular infiltrate in the alveolar walls with or without an accumulation of large mononuclear cells in the alveolar spaces) also respond better.^{3 5 7}

In the present report we attempt to distinguish

Address for reprint requests: Professor M Turner-Warwick, Cardiothoracic Institute, Brompton Hospital, Fulham Road, London SW3 6HP.

factors influencing an early response to treatment (in terms of subjective or objective improvement) and the influence of steroid treatment on survival.

Methods

The definition of CFA has been given in a previous paper.⁸ Two hundred and twenty cases fulfilling criteria for CFA who attended any one of 13 physicians at the Brompton Hospital between 1955 and 1973 were reviewed retrospectively and a minimum of a four-year follow-up completed to 31 January 1977. All deaths were verified in the Births and Deaths Register. Adequate follow-up information was obtained in 209 cases. Fifty-three are known to be alive and 156 have been followed to death. Eleven patients are believed to be alive but no details are available; no information regarding the cause of death is available in four of the 156 cases.

The clinical features of this population and the overall life table analyses of survival have already been reported.⁸

Over the 22 years spanned by this study physicians varied in their treatment of CFA. Because of these varied individual policies steroids were not used for a number of different reasons in 77 of the 220 (35%) and were given to 143 (65%). In 32 instances corticosteroids were started before attendance at Brompton and in some analyses these cases will be compared with those who started treatment after attendance at Brompton because there is evidence that the former group may have been referred because they had failed to respond to steroids. Thus, 111 (78%) of the steroid-treated cases started treatment at our hospital. However, in every case treatment was started after 1955—that is, at the beginning of the survey. The mean age at onset of symptoms was 54.9 years $\pm$ 12 SD and the mean age at the start of steroids was 56.0 years $\pm$ 11.0 SD.

The initial doses of corticosteroids given varied and are set out in table 1. Although the exact dose and duration of treatment varied considerably treatment continued indefinitely, usually at a reduced level.

Table 1 Doses of oral corticosteroids in treated patients with cryptogenic fibrosing alveolitis*

Dose of prednisone or prednisolone in mg/day	Treated patients	
	Number	%
10–15	24	16.8
20–25	30	21.0
30–35	35	24.5
40–45	29	20.2
50–60	14	9.8
Dose unknown	11	7.7
Total treated	143	100.0

*Mean dose 30.3 mg/day $\pm$ 13.3 SD

*Doses at time of assessment of response

The subjective response to steroids was assessed by review of the patients' hospital notes regarding change in dyspnoea at four to eight weeks after the start of treatment, when patients were usually still receiving their initial high dose. Improvements in other symptoms including general wellbeing have not been included in the definition of subjective improvement. Improvement of dyspnoea was graded as "much improved," "slightly improved," "initial improvement" (but relapsing as the dose was reduced), and "none." In this report cases have been regarded as steroid-responsive if they had much improvement or initial improvement and unresponsive if they showed slight or no improvement.

Objective change was assessed comparing standard physiological data before and after four to eight weeks of treatment including measurement of forced expiratory volume in one second (FEV₁), forced vital capacity (FVC), total lung capacity (TLC), and FEV₁/FVC ratio. The method of measuring transfer factor for carbon monoxide changed during the course of the follow-up period and has not been included in this paper. All the physiological results are presented here as a percentage of the predicted value. Radiographic change was assessed by paired film analysis, the reader being unaware of the chronological order of the films. All films were also read blind by one reader using the ILO/UICC classification system.⁹

Gratings for the clinical, physiological, radiographic, and histological features have been described previously.⁸

Survival analysis has been undertaken using a log rank survival routine devised by Peto *et al*,¹⁰ in which allowance for age, sex, and other factors can be made when considering the influence of other variables on survival.

Results

Of 220 patients, 143 were treated with corticosteroids. Table 2 shows the characteristics of the two groups. The only feature showing a significant difference was the age at onset of dyspnoea and at presentation (fig 1).

STEROID RESPONSE

Sufficient information was available in 127 of the 143 cases, but in three of these 127 detailed follow-up information was not available. After four to six weeks treatment, no improvement was observed in 42 (33%), slight subjective improvement in 13 (10%), initial improvement in 26 (21%), and good subjective improvement in 46 (36%). Thus 55 (43%) were classified as non-responders and 72 (57%) as responders.

Table 2 Comparison between the clinical features of the untreated and treated cases

Features	Untreated (n=77)		Treated (n=143)		p
	Mean $\pm$ SD or number	%	Mean $\pm$ SD or number	%	
Sex—male	55	71	92	64	NS
Age at presentation	61.0 yr $\pm$ 11		55.7 yr $\pm$ 11		0.001
Duration of dyspnoea	2.0 $\pm$ 2.6 yr		2.3 $\pm$ 3.2 yr		NS
Grade of dyspnoea	1.4		1.7		NS
Right heart failure at present	7	9	9	6	NS
Smoker	62	80	100	70	NS
Polyarthrititis	13	17	33	23	NS
Other immunological disease	8	10	16	11	NS
Physiology					
FEV ₁ % predicted	67.9 $\pm$ 18		60.7 $\pm$ 19		0.07
FVC % predicted	66.5 $\pm$ 17.7		62.7 $\pm$ 19		NS
TLC % predicted	74.2 $\pm$ 18.0		74.9 $\pm$ 22		NS
PaO ₂ mmHg	62.8 $\pm$ 16.9		61.3 $\pm$ 16.2		NS
Radiographic					
Zones	4.2 $\pm$ 1.6		4.1 $\pm$ 1.7		NS
Profusion scores of irregular opacities	1.9 $\pm$ 0.7		1.7 $\pm$ 0.8		NS
Biopsy	(n=7)		(n=35)		
Intra-alveolar mononuclear	None/few Many	4 3	17 18	49 51	NS NS
Interstitial lymphocytes	None/few Many	4 3	23 12	66 34	NS NS
Fibrosis	None or little Much	2 3	23 12	66 34	NS NS
Overall	Cellular Fibrotic Mixed	2 3 2	14 14 7	41 41 18	NS NS NS
ANA $\geq$ 1/10	32/70	45.7	56/122	45.9	NS
DAT $\geq$ 1/32	12/70	17	20/122	16.4	NS
ESR mm/1 hr	36.0 $\pm$ 26.5		32.6 $\pm$ 25.1		NS

Fig 1 Histogram to show the ages at presentation in treated and untreated groups of patients with cryptogenic fibrosing alveolitis.

Complete clinical, radiographic, and physiological data before and after steroid treatment were available for review in 78 cases. Thirty-five (45%) of these showed improvement of dyspnoea and 13 of those with improved dyspnoea also showed improvement in the radiograph. Although 29 of the 35 also showed

an improvement of at least 10% in the FVC, only one patient with subjective improvement of dyspnoea showed a greater than 20% improvement in FVC.

Of the 78 treated patients whose full assessment data were available, only 11 (14%) showed improvement in dyspnoea, as well as improvement in the physiological measurements (FVC greater than 10%) and the radiograph.

The clinical features of those responding and not responding to treatment are set out in table 3. The only significant features associated with a good steroid response were younger individuals ($p < 0.001$) (fig 2) and less severe dyspnoea at presentation ($p < 0.02$). Analyses of the biopsies using a semi-quantitative method did not identify steroid responders although there was a trend towards greater numbers of responders having a cellular biopsy with less fibrosis. The presence of immunological disease and the radiographic scores did not differ between the groups. The complications of steroid treatment are listed in table 4 and this shows that about one-quarter of the patients developed important side-effects.

SURVIVAL

Survival data have been analysed in terms of life-table survival curves and by analysis of groups of cases dead in less than two years, within two to four

Table 3 Comparison between the clinical features of steroid responsive and unresponsive cases

Features	No response (n = 55)		Good response (n = 72)		p
	Mean $\pm$ SD or number	%	Mean $\pm$ SD or number	%	
Sex—male		73		61	NS
Age at onset (yr)	57.3 $\pm$ 8.5		49.0 $\pm$ 12		0.001
Age at presentation (yr)	59.0 $\pm$ 8.0		51.5 $\pm$ 11.8		0.001
Duration of dyspnoea	2.4 $\pm$ 2.8		2.7 $\pm$ 3.8		NS
Grade of dyspnoea	2.0 $\pm$ 1.2		1.5 $\pm$ 0.8		0.02
Smoker	41/45	74	45/70	64	NS
Polyarthritis	13	24	11	15	NS
Other immunological disease	5	9	11	15	NS
<i>Physiology</i>					
FEV ₁ % predicted	60.1 $\pm$ 19.3		62.9 $\pm$ 17.8		NS
FVC % predicted	63.7 $\pm$ 20.8		61.1 $\pm$ 17.0		NS
TLC % predicted	72.8 $\pm$ 24.1		77.0 $\pm$ 22.6		NS
PaO ₂ mmHg	58.8 $\pm$ 18		63.7 $\pm$ 15		NS
<i>Radiographic</i>					
Zones	4.0 $\pm$ 1.8		4.1 $\pm$ 1.7		NS
Profusion scores of irregular opacities	1.8 $\pm$ 0.8		1.7 $\pm$ 0.8		NS
Improvement in film	4/11	18	16/36	50	0.05
<i>Biopsy</i>	(n = 14)		(n = 18)		
Intra-alveolar mononuclear	None/few Many	7 7	8 10	44 56	NS NS
Interstitial lymphocytes	None/few Many	9 5	11 7	61 39	NS NS
Fibrosis	None or little Much	9 5	13 5	72 28	NS NS
Overall	Cellular Fibrotic Mixed	4 6 4	10 6 2	56 33 11	NS NS NS
ANA $\geq$ 1/10	24/51	47	32/69	45	NS
DAT $\geq$ 1/32	8/52	15	12/70	17	NS
ESR mm/1 hr	34 $\pm$ 32		31 $\pm$ 27		NS

Fig 2 Histogram to show the age distribution of the group of patients responding to corticosteroids (assessment made four to eight weeks after starting treatment) and those showing no response.

years, and alive at four years. The analyses undertaken correlate closely and the results have been pooled (fig 3).

The median survival of untreated patients was 54 months. A longer survival was observed in women ($p < 0.03$), and in those presenting at a younger age ($p < 0.02$) (table 5). These factors influenced survival independently in that the differences per-

Table 4 Steroid complications in 127 patients

	Number	% Frequency
None	94	74
Fluid overload	12	9
Hypertension	6	5
Peptic ulcer	6	5
Osteoporosis	5	4
Tuberculosis	3	2
Diabetes	1	1

There were overall complications in about 26%.

Table 5 Analysis of factors influencing survival in untreated and treated cases

Features	Untreated cases (n = 77)	p	Treated cases (n = 143)	p
	Factors with better survival		Factors with better survival	
Sex	Females	0.03		NS
Age at onset of symptoms (yr)	Younger	0.06	Younger	0.01
Age at presentation (yr)	Younger	0.02	Younger	0.001
Grade of dyspnoea		NS	Lesser grade	0.03
Radiographic score		NS	Lesser profusion	0.002
Histology		NS	More cellular	0.01
Early steroid response			Good response*	0.001

*A good steroid response was associated with improved survival after correction (for comparability with non-responders) for all other factors except histology.

Fig 3 Survival curve for steroid responsive, steroid failures, and untreated patients.

sisted when appropriate adjustments for age and sex had been made. Survival in untreated patients was not related to any other factors analysed.

Among the treated patients a longer survival was noted not only in the younger patients but also in those with less dyspnoea ($p < 0.03$), lesser radiographic profusion ($p < 0.002$), and greater cellularity of the biopsy ($p < 0.01$).

There was a strong relationship between longer survival and an early good response to steroids ($p < 0.001$). The improved survival seen in the good steroid responders was still observed after corrections (to be comparable with non-responders) had been made for age, sex, duration and severity of dyspnoea, physiological and radiological severity, the presence of immunological disease, autoantibodies, and the presence of right heart failure. The significant effect on survival is, however, eliminated when corrected for cellularity of the biopsy, suggesting that the effect of steroids is closely linked with more acute histological changes.

In an attempt to obtain evidence of stabilisation of disease by steroids irrespective of early subjective or objective improvement, the survival of steroid treated and untreated groups were compared but no overall difference was observed even after age and sex correction. Of 55 steroid non-responders 10 (18%) were still alive at the end of four years and this was significantly worse than the 31 (40%) of 77 untreated cases alive after a similar period ($p < 0.05$). However, analyses not detailed here show that the steroid non-responders tend to have more severe disease at presentation than the untreated group, which limits the significance of this comparison.

FOLLOW-UP DATA ON THOSE LIVING COMPARED WITH THOSE DEAD

One hundred and fifty-six patients have been

followed to death and 53 are still alive. The mean survival of those followed to death was $3.4 \text{ years} \pm 3.7 \text{ SD}$ and of those surviving $8.8 \text{ years} \pm 3.8 \text{ SD}$. Of the living treated patients in whom the response was known, 25 (69%) of 36 showed good improvement compared with the treated patients who died, where only 19 (22%) of 88 showed such a response ($p < 0.001$).

Discussion

That corticosteroid treatment is associated with subjective and objective improvement within a few weeks in a group of patients having signs and symptoms of disease over a much longer period of time is good evidence that steroids are directly related to such a response. Although a formal analysis of clinical change at four to eight weeks was not systematically recorded in the untreated patients in this retrospective study, nevertheless follow-up review of the radiographs and physiological measurements in the untreated group not reported in detail in this paper shows that objective improvement rarely occurred. This is in accord with Carrington *et al*² who showed that no case of usual interstitial pneumonia improved spontaneously over a six to 12 month period.

The frequency of subjective or objective improvement observed after four to eight weeks treatment is similar to that in previous reports (table 6). The present study has shown that steroid responsiveness assessed after one to two months trial of therapy is reflected in an improved long-term survival as suggested by Stack *et al*.³

While an early prediction of prognosis is of clinical importance, it cannot be concluded that a longer survival is necessarily caused by steroid treatment. An alternative explanation is that steroid

Table 6 *Reported frequency of steroid responsiveness in cryptogenic fibrosing alveolitis or usual interstitial pneumonia*

	Number of cases studied	Subjective improvement Number % improved	Subjective and objective improvement Number % improved
Stack <i>et al</i> ³	69	28 41	11 16
Carrington <i>et al</i> ²	26	Not recorded	3 12
Murao <i>et al</i> ⁴	131	92 70	31 24
Wright <i>et al</i> ⁵	40	24 60	12 30
Present series	78	35 45	13 17
Totals	344	179 25	70 20

responsiveness identified a subgroup of patients having an inherently better prognosis. This suggestion is supported by the observation that the survival curve for untreated cases (which as we have demonstrated appears to have characteristics very comparable to the treated group) lies *between* that for good and that for poor responders (fig 3). Further support for this argument is obtained from the analysis of factors influencing the difference between the survival curves for good and non-responders. Using the log rank method¹⁰ to make allowance for many factors relating to severity of disease, survival in the responsive group remained better than in the non-responders. However, when allowance was made for cellularity of the biopsy (of mixed inflammatory cells but not necessarily fulfilling criteria for DIP) the difference in survival between the two groups was eliminated. This suggests that the improved survival in the steroid responsive group is closely related to a cellular biopsy; whether this be by association or by cause and effect is not proved. Unfortunately histology was not available in enough untreated cases to demonstrate conclusively whether a cellular biopsy implies as good a prognosis in this group as in the steroid responsive group, although some effect was observed in that all three patients with a "fibrotic" biopsy were dead within two years while both patients with a cellular biopsy were alive after 17 and 13 years. On the other hand, there are three pieces of evidence which suggest that steroids have an influence on survival, beyond identifying a group with a better prognosis. First, if the latter was so, the factors relating to a better survival in the treated and untreated groups should be identical but this is shown not to be the case (table 5). A better survival among treated cases can be identified with a number of factors relating to earlier disease which are not significantly related to a better survival in untreated cases. This suggests that steroids are having some additional influence on survival. Second, on the hypothesis that steroid responsiveness operates only as a marker for a subgroup with an inherently better prognosis, then once identification of this has been

obtained at one to two months, it should be possible to stop steroids at this point without relapse and with good survival. Although this has never been tested formally it is common experience that relapse occurred not infrequently as the dose of steroids is reduced. Thirdly, the fact that the group with better survival has been defined in terms of subjective or objective improvement or both, strongly suggests that steroids have a direct influence on lung pathology.

In summary, the analyses presented here suggest to us that steroid responsiveness occurs especially in a subgroup of patients who have to some extent an inherently better prognosis and that this probably includes younger patients with more cellular pathology. Nevertheless our data provides some evidence that steroid therapy has an additional influence on survival in some patients.

It is also important to establish whether steroids can increase survival without short-term measurable improvement. No evidence was found for this in the present study when the survival of untreated cases was compared with that of the group unresponsive to steroids. Indeed the survival of the untreated patients was better than that of non-responders. This observation might suggest that steroids actually accelerate the course of disease in some instances. Before attributing such sudden deterioration to steroids it must also be noted that we have observed sudden acceleration in progression in individual patients before introduction of steroids and indeed this is not infrequently the reason for their referral to hospital. On the other hand the fact that the correlation between cellular histology and survival was stronger than the correlation between cellular histology and steroid responsiveness suggests that corticosteroids may arrest the inflammatory component of disease without actual monitored improvement in some cases.

Finally a comment should be made about the early deaths among the steroid responsive group. Some of these were from unrelated causes in the middle-aged and elderly population. Others may well have been caused by a reduction of steroid doses without adequate and careful monitoring of the clinical response in the individual patient. Other cases however showed an initial response and in spite of careful observation and titration of drug, relapsed. The reason for this transient response is unknown but has been observed in our current prospective survey.

We should like to thank all the Physicians at the Brompton Hospital for allowing us to review their patients. Dr KWF Hinson kindly assessed the lung biopsies. We also thank Miss Ruth Honey for her painstaking help with documentation.

References

- 1 Liebow AA, Steer A, Billingsley JG. Desquamative interstitial pneumonia. *Am J Med* 1965; **39**:369–404.
- 2 Carrington CB, Gaensler EA, Coutu RE, Fitzgerald MX, Gupta RG. Natural history and treated course of usual desquamative interstitial pneumonia. *N Engl J Med* 1978; **298**:801–9.
- 3 Stack BHR, Choo-Kang YFJ, Heard BE. The prognosis of cryptogenic fibrosing alveolitis. *Thorax* 1972; **27**:535–42.
- 4 Murao M. Idiopathic pulmonary fibrosis. Report of the nationwide project research in Japan. XIII World Congress on Diseases of the Chest. *Chest* 1980; in press.
- 5 Wright PH, Heard BE, Steel SJ, Turner-Warwick M. Trephine biopsy histology in the management of cryptogenic fibrosing alveolitis. In preparation.
- 6 Livingstone JL, Lewis JG, Reid L, Jefferson KE. Diffuse interstitial pulmonary fibrosis. A clinical, radiological and pathological study on 45 patients. *Q J Med* 1964; **233**:71–102.
- 7 Dreisin RB, Schwartz MI, Theofilopoulos AN, Stanford RE. Circulating immune complexes in the idiopathic interstitial pneumonias. *N Engl J Med* 1978; **298**:353–7.
- 8 Turner-Warwick M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis: clinical features and their influence on survival. *Thorax* 1980; **35**:171–80.
- 9 UICC Committee. Cincinnati classification of the radiographic appearances of pneumoconioses: a co-operative study by the UICC Committee. *Chest* 1970; **58**:57–67.
- 10 Peto R, Pike MC, Armitage P *et al.* Design and analysis of randomized clinical trials requiring prolonged observation of each patient. *Br J Cancer* 1977; **35**:1–39.